Prognostic factors of short-term outcomes of intravitreal ranibizumab in diabetic macular edema

Prognostic factors of short-term outcomes of intravitreal ranibizumab in diabetic macular edema

Blog Article

AIM: To evaluate the prognostic factors for short-term HONEY COMB visual and anatomical improvement of intravitreal ranibizumab (IVR) for diabetic macular edema (DME).METHODS: Fifty-one eyes from 35 patients that received three consecutive monthly IVR for DME with moderate visual loss were retrospectively recruited; all cases had their baseline best-corrected visual acuity (BCVA) between 20/400 and 20/40.BCVA and central subfield thickness (CST) at baseline and month 3 were collected.Linear mixed models were used to evaluate the prognostic factors for visual and anatomical improvement at month 3.RESULTS: Younger age, poorer baseline BCVA and proliferative diabetic retinopathy (PDR) were correlated with better visual improvement at month 3 (P=0.

002, 0.0001 and 0.007, respectively).Thicker CST and the presence of subretinal fluid at baseline were correlated with a greater reduction in CST (P0.05 for both).

CONCLUSION: For eyes with DME and moderate visual loss, those with younger age, poorer baseline BCVA or PDR tend to have better visual improvement after Course a pied - Homme - Vetements - Manteau - Duvet three consecutive monthly IVR.Epiretinal membrane or previous PSTA result in less resolution of CST, but do not significantly affect visual improvement.